Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Suspends Shipments of MR Vaccine as Quality Issue Drags On
Takeda Pharmaceutical said on November 29 that it is temporarily suspending shipments for its measles-rubella (MR) vaccine as it needs more time to identify the cause of quality issues detected for the shot and evaluate countermeasures. In January this year,…
To read the full story
Related Article
- Takeda to Resume MR Vaccine Shipments in June after Potency Issue
March 30, 2026
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Daiichi Sankyo, Takeda Restricting Shipments of Mumps Vaccines
February 3, 2025
- Daiichi, Mitsubishi Curb MR Vaccine Shipments in Response to Takeda’s Recall
January 19, 2024
BUSINESS
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- Meiji Backs US Fund Supporting Pandemic Preparedness
June 1, 2026
- Kaken, Gilead Ink Japan Sales Partnership for Seladelpar
June 1, 2026
- Shionogi’s OIC Drug Naldemedine Bags Approval in China
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…